← Back

Alkermes Plc

Alkermes plc is a biopharmaceutical company that researches, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Ireland, and internationally. Its portfolio includes proprietary commercial products for opioid dependence, alcohol dependence, schizophrenia, and bipolar I disorder, along with clinical and preclinical candidates for neurological disorders. Marketed products include ARISTADA and ARISTADA INITIO for schizophrenia, VIVITROL for alcohol dependence and prevention of opioid dependence, LYBALVI for schizophrenia and bipolar I disorder, and LUMRYZ for cataplexy or EDS in pediatric patients. The company also provides proprietary technology platforms to third parties and has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Founded in 1987, Alkermes plc is headquartered in Dublin, Ireland.

Price · split & dividend adjusted
News & notes moving ALKS
United States
Biotech & Genomic Medicine▲3

Alkermes Reports First ADHD Data for Orexin Agonist ALKS 7290

Alkermes plc reported positive topline results from a phase 1b proof-of-concept study of ALKS 7290, an investigational orexin 2 receptor agonist, which showed clinically meaningful, dose-dependent improvements in adult ADHD symptoms over 14 days with a generally well-tolerated safety profile. These data represent the first clinical evidence of an orexin receptor agonist's effects in ADHD, potentially widening Alkermes' orexin franchise beyond sleep disorders and other neurologic indications already under exploration. The ALKS 7290 news follows the launch of the Brilliance phase 3 alixorexton studies in narcolepsy earlier in 2026. Alkermes' narrative projects $2.3 billion revenue and $374.7 million earnings by 2029, requiring 10.6% yearly revenue growth and about a $308.6 million earnings increase from $66.1 million today, while the most cautious analysts had penciled in only about 7.5% annual revenue growth and US$333.7 million of 2029 earnings.
ALKS ▲
Biotech & Genomic Medicine ▲
About megatrends
Biotech & Genomic Medicine › Neuroscience & Neurodegenerative ▲Demand
ALKS · Technology · Positive Positive phase 1b topline results show ALKS 7290 produced clinically meaningful, dose-dependent ADHD symptom improvements, the first clinical evidence of an orexin agonist in ADHD.
Read original ↗
Simply Wall St·11dRead more →
IrelandUnited States
ALKS

Alkermes Appoints Anne C. Whitaker to Board of Directors

Alkermes plc announced the appointment of Anne C. Whitaker as a new independent director to its Board of Directors. Whitaker is a seasoned biopharmaceutical executive and experienced board director, most recently serving as chief executive officer of Aerami Therapeutics, and previously holding CEO roles at Novoclem Therapeutics and Synta Pharmaceuticals, along with senior commercial and executive positions at Bausch Health Companies, Sanofi and GlaxoSmithKline. She currently serves on the boards of publicly traded Basilea Pharmaceutica and ICON plc, as well as private companies QurAlis, Bespak, Beaconcure Technologies and Trinity Partners. President and Chief Executive Officer Blair Jackson said Whitaker joins at a defining time as the company builds on strong commercial performance and advances a differentiated neuroscience pipeline, while Chairman Richard Pops cited her executive and board experience across organizations of varying sizes and stages. Alkermes, headquartered in Ireland, is a global biopharmaceutical company developing medicines in neuroscience, with commercial products for alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder and narcolepsy.
ALKS
ALKS · · Neutral Alkermes appoints Anne C. Whitaker as an independent director; a board change with no clear operational or financial driver.
Read original ↗
Business Wire·18dRead more →
United States
ALKS▼

Alkermes Stock Drops 5% Despite Revenue Surge as GAAP Net Income Narrows to $0.5 Million

Alkermes plc shares fell 5% to $50.05 after its second-quarter 2026 report showed a 27% revenue jump to $496.0 million but GAAP net income collapsed to $0.5 million from $87.1 million a year earlier. Proprietary net sales reached $411.7 million, led by VIVITROL at $124.5 million, ARISTADA at $96.7 million, LYBALVI at $94.0 million, and newly integrated narcolepsy therapy LUMRYZ at $96.6 million, while manufacturing and royalty revenues added $79.0 million. Adjusted EBITDA grew to $139.2 million, yet integration costs and higher R&D and SG&A spending weighed on bottom-line earnings. The company also announced that CEO Richard Pops will become Executive Chairman and COO Blair Jackson will take over as CEO on August 1.
ALKS ▼
ALKS · Capital · Negative GAAP net income collapsed to $0.5M from $87.1M despite revenue surge, and shares fell 5%.
Read original ↗
Insider Monkey·54dRead more →
ALKS▼

Alkermes shares pull back after mixed Q2 results, fair value debate splits analysts

Alkermes shares fell 7.37% over the past week to US$48.99 after the company reported second-quarter 2026 results that showed higher revenue but a significantly lower quarterly net income. The most-followed narrative on Simply Wall St pegs fair value at US$47.69, suggesting the stock is about 3% overvalued, while the platform's own discounted cash flow model estimates fair value at US$99.55, roughly 51% above the current price. The bullish case rests on strong demand for proprietary neuroscience products Vivitrol, Aristada, and Lybalvi, driven by expanding diagnosis rates and greater patient access, though risks remain around orexin trial outcomes and product concentration. Longer-term returns remain robust, with a 90-day share price gain of 46.76% and a one-year total shareholder return of 84.52%.
ALKS ▼
ALKS · Capital · Negative Mixed Q2 results with lower net income and analyst fair value debate weigh on shares.
Read original ↗
Simply Wall St·65dRead more →
Biotech & Genomic Medicine▲

Alkermes Shares Rise 9.3% on Positive Alixorexton Phase 2 Data and Russell 2000 Addition

Alkermes shares climbed 9.3% after the company reported detailed positive phase 2 Vibrance‑2 results for its oral orexin 2 receptor agonist alixorexton in narcolepsy type 2 and was added to the Russell 2000 Dynamic Index. The Vibrance‑2 data met dual primary endpoints on wakefulness and daytime sleepiness with sustained benefits, and showed encouraging safety and patient‑reported gains in fatigue and cognition. These results sharpen focus on the upcoming phase 3 Brilliance program as the key catalyst for Alkermes' orexin pipeline, which the company hopes will become a meaningful new pillar alongside Vivitrol, Aristada, and Lybalvi. The Russell 2000 Dynamic Index inclusion is seen as visibility‑enhancing but not a material driver of the core risk‑reward balance. Alkermes' narrative projects $2.1 billion in revenue and $264.8 million in earnings by 2029, requiring 11.1% yearly revenue growth.
ALKS ▲
Biotech & Genomic Medicine ▲
About megatrends
Biotech & Genomic Medicine › Neuroscience & Neurodegenerative ▲Technology
ALKS · Technology · Positive Positive phase 2 data for alixorexton in narcolepsy type 2, meeting dual primary endpoints with sustained benefits.
ALKS · Capital · Positive Addition to Russell 2000 Dynamic Index, enhancing visibility but not a material driver.
Read original ↗
Simply Wall St·96dRead more →
Biotech & Genomic Medicine▼2impact 4

Alkermes plummets after mid-stage narcolepsy data for alixorexton

Alkermes shares fell about 31% in after-hours trading Wednesday after the company reported phase 2 results for its narcolepsy type 2 drug candidate alixorexton. The Vibrance-2 trial met its dual primary endpoints, showing statistically significant improvements from baseline on the Maintenance of Wakefulness Test and the Epworth Sleepiness Scale at week eight compared to placebo. Patient-reported improvements in wakefulness were maintained through a five-week open-label extension, and those on alixorexton also saw improvements in fatigue versus placebo, with no serious treatment-emergent adverse events reported. Alkermes said it has begun a phase 3 program examining once-daily and split dose regimens of the oral selective orexin 2 receptor agonist.
ALKS ▼
Biotech & Genomic Medicine ▼
About megatrends
Biotech & Genomic Medicine › Neuroscience & Neurodegenerative ▼Technology
ALKS · Technology · Negative Phase 2 data for alixorexton met endpoints but stock fell 31% after hours, likely due to market disappointment with the magnitude of effect or safety profile.
Read original ↗
Seeking Alpha·109dRead more →
© 2026 MarketDXAsset